Mendole A/S publishes Interim Report Q2 2026

Mendole reported H1 2026 revenue of DKK 65.5m (+~11% Y/Y) but swung to an EBITDA loss of DKK -3.4m (vs +DKK 0.8m in H1 2025). The net result also deteriorated to DKK -5.0m, attributed to a soft early-season market and geopolitical disruptions. Overall, the topline grew while profitability weakened materially.

Analysis

The key signal is not the top-line growth; it’s that incremental revenue is not converting into operating profit, which usually earns a lower multiple in small-cap equities. In the near term, that tends to pressure the stock because investors had been implicitly paying for leverage that is not showing up, and liquidity in names like this can exaggerate the downside on a weak print.

Competitive dynamics likely favor better-capitalized rivals that can keep investing through a soft seasonal patch while Mendole is forced to protect volume or absorb higher servicing/logistics costs. If the disruption is temporary, the second-order effect is still a share-shift: customers and suppliers tend to re-rate reliability, so even a short earnings miss can become a multi-quarter loss of bargaining power.

The contrarian view is that this could be a timing problem rather than a demand problem, especially if the business is back-half weighted and the early-year weakness was amplified by one-off geopolitical friction. The thesis is falsified if management shows a clean H2 margin bridge, working-capital release, or raises full-year EBITDA guidance; absent that, the risk is that modest revenue growth masks a longer period of cash burn and a de-rating into the next two reporting cycles.

Key Decisions for Investors

• If MENDO-ST is sufficiently liquid, fade any 1-2 day relief bounce with a tactical short; target a move back toward pre-print levels over 1-3 months, and cover if management explicitly reaffirms full-year EBITDA breakeven or better.
• Do not buy the revenue growth story until there is evidence of operating leverage: require either two consecutive quarters of margin improvement or a revised FY guide that implies H2 EBITDA inflection; otherwise treat rallies as sellable.
• Set a watch item for next catalyst: any update on seasonality, customer demand, or geopolitical normalization over the next 30-90 days. If those factors reverse and gross margin improves faster than revenue, the stock could re-rate sharply from deeply discounted levels.
• If borrow is constrained or liquidity is thin, avoid an outright short and instead wait for a higher-confidence setup after the next operating update; the risk/reward is not compelling enough to force a position today.